ストックスクリーナーアプリを入手
0.6901
2.11%
-0.0148
アフターアワーズ：
.70
0.00995
+1.44%
Mink Therapeutics Inc (INKT) 最新ニュース
MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird - Defense World
Bright Mountain Media, Inc. Enters into Executive Employment Agreement with CEO Matthew DrinkwaterOn November 8, 2024, Bright Mountain Media, Inc. (OTCMKTS:BMTM) announced in an 8-K filing that they had entered into an Executive Employment Agr - Defense World
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q3 2024 Earnings Call Transcript - Insider Monkey
MiNK Therapeutics stock target cut, rating held amid pipeline updates By Investing.com - Investing.com UK
MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
MiNK Therapeutics Reports Q3 Growth and Strategic Advances - TipRanks
Earnings call: MiNK Therapeutics succeeded in reducing costs by 60% - Investing.com
MiNK Therapeutics Inc (INKT) Quarterly 10-Q Report - Quartzy
Agenus (AGEN) Stock Dips Amid Financial Performance and Industry Trends - GuruFocus.com
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update - GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report - GlobeNewswire
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MiNK Therapeutics Sets Q3 2024 Earnings Call: iNKT Cell Therapy Updates Ahead | INKT Stock News - StockTitan
Hedge funds pile into banks, dump green energy post US election, Goldman Sachs says - Yahoo Canada Finance
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 - GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid - The Bakersfield Californian
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Makes New Investment in Team, Inc. (NYSE:TISI) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Investor’s Toolkit: Key Ratios for Assessing MiNK Therapeutics Inc (INKT)’s Performance - The Dwinnex
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration - TipRanks
ZenaTech's ZenaDrone Commences Aerial Operations to Commercialize Drone Services in the US Following FAA Approval - The Manila Times
MiNK Therapeutics and Autonomous Therapeutics Announce - GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors - Yahoo Finance
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges - Investing.com
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):